Silver Book Fact

Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.

Papaioannou A, Watts N, Kendler D, et al. Diagnosis and Management of Vertebral Fractures in Elderly Adults. Am J Med. 2002; 113(3): 220-8. http://www.amjmed.com/article/S0002-9343(02)01190-7/abstract

Reference

Title
Diagnosis and Management of Vertebral Fractures in Elderly Adults
Publication
Am J Med
Publication Date
2002
Authors
Papaioannou A, Watts N, Kendler D, et al
Volume & Issue
Volume 113, Issue 3
Pages
220-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…